CYTOKINETICS, INCORPORATED Restructuring Costs and Asset Impairment Charges
CYTOKINETICS, INCORPORATED (CYTK) reported Restructuring Costs and Asset Impairment Charges of $0 for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2015-03-06
- CYTOKINETICS, INCORPORATED restructuring costs and asset impairment charges for the quarter ending 2012-12-31 was $0.00.
- CYTOKINETICS, INCORPORATED restructuring costs and asset impairment charges for the quarter ending 2012-09-30 was -$2.00K.
- CYTOKINETICS, INCORPORATED restructuring costs and asset impairment charges for the quarter ending 2012-06-30 was -$13.00K.
- CYTOKINETICS, INCORPORATED restructuring costs and asset impairment charges for the quarter ending 2012-03-31 was -$41.00K.
- CYTOKINETICS, INCORPORATED restructuring costs and asset impairment charges for fiscal 2014 was $0.00.
- CYTOKINETICS, INCORPORATED restructuring costs and asset impairment charges for fiscal 2013 was $0.00.
- CYTOKINETICS, INCORPORATED restructuring costs and asset impairment charges for fiscal 2012 was -$56.00K, a 128.87% decline from fiscal 2011.
- CYTOKINETICS, INCORPORATED restructuring costs and asset impairment charges for fiscal 2011 was $194.00K.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 9 month | Restructuring Costs and Asset Impairment Charges 12 month | Restructuring Costs and Asset Impairment Charges 167 month | Restructuring Costs and Asset Impairment Charges 170 month | Restructuring Costs and Asset Impairment Charges 173 month | Restructuring Costs and Asset Impairment Charges 176 month | Restructuring Costs and Asset Impairment Charges 179 month | Restructuring Costs and Asset Impairment Charges 182 month | Restructuring Costs and Asset Impairment Charges 185 month | Restructuring Costs and Asset Impairment Charges 188 month | Restructuring Costs and Asset Impairment Charges 191 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-12-31 | $0.00 10-K · filed 2015-03-06 | ||||||||||||
| 2013-12-31 | $0.00 10-K · filed 2015-03-06 | ||||||||||||
| 2013-06-30 | $636.00K 10-Q · filed 2013-08-07 | ||||||||||||
| 2013-03-31 | $636.00K 10-Q · filed 2013-05-08 | ||||||||||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-06 | -$2.00K derived: sum of 2 quarters · filed 2015-03-06 | -$15.00K derived: sum of 3 quarters · filed 2015-03-06 | -$56.00K 10-K · filed 2015-03-06 | $636.00K 10-K · filed 2013-03-15 | ||||||||
| 2012-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | -$15.00K derived: sum of 2 quarters · filed 2013-08-07 | -$56.00K 10-Q · filed 2012-11-07 | $636.00K 10-Q · filed 2012-11-07 | |||||||||
| 2012-06-30 | -$13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | -$54.00K 10-Q · filed 2013-08-07 | $638.00K 10-Q · filed 2012-08-06 | ||||||||||
| 2012-03-31 | -$41.00K 10-Q · filed 2013-05-08 | $651.00K 10-Q · filed 2012-05-04 | |||||||||||
| 2011-12-31 | $194.00K 10-K · filed 2014-03-07 | $692.00K 10-K · filed 2012-03-13 | |||||||||||
| 2011-09-30 | $498.00K 10-Q · filed 2011-11-04 | ||||||||||||
| 2011-06-30 | $498.00K 10-Q · filed 2011-08-04 | ||||||||||||
| 2009-12-31 | $22.00K 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |